# CKD-330 Phase 3 Trial in Amlodipine Non-responder

> **NCT02586311** · PHASE3 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 160 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** CKD-330 16/5mg
- **DRUG:** Amlodipine 5mg Placebo
- **DRUG:** CKD-330 16/5mg Placebo
- **DRUG:** Amlodipine 5mg

## Key facts

- **NCT ID:** NCT02586311
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2016-08
- **Final completion:** 2016-09
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2016-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02586311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02586311, "CKD-330 Phase 3 Trial in Amlodipine Non-responder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02586311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*